{
    "2021-01-28": [
        [
            {
                "time": "",
                "original_text": "浙商证券----医药行业周报：CXO/IVD业绩预喜，疫情下持续高景气【行业研究】",
                "features": {
                    "keywords": [
                        "CXO",
                        "IVD",
                        "业绩预喜",
                        "疫情",
                        "高景气",
                        "医药行业"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "2022-01-18至2022-01-22",
                "original_text": "上周（1月18日-1月22日），8家医药公司总市值均突破1000亿元",
                "features": {
                    "keywords": [
                        "医药公司",
                        "总市值",
                        "突破1000亿元"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "这12家药企2020年预计净利润增速超过30%",
                "features": {
                    "keywords": [
                        "药企",
                        "2020年",
                        "净利润增速",
                        "超过30%"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "净利预计增速翻倍，高位回落的康龙化成（03759）赶上国内CRO红利期",
                "features": {
                    "keywords": [
                        "康龙化成",
                        "净利增速翻倍",
                        "高位回落",
                        "CRO红利期"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "CRO"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "mixed"
                }
            },
            {
                "time": "",
                "original_text": "港股盘前必读：中国中药在香港暂停交易或被私有化",
                "features": {
                    "keywords": [
                        "港股",
                        "中国中药",
                        "暂停交易",
                        "私有化"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}